Who is Andy Ngo? From photographer at a used car dealership to one of America’s most polarizing media figures – MEAWW

Controversial journalist Andy Ngo found himself in the headlines on Twitter on Sunday, August 2, with people seeking micro-blogging site to unverify him. The man is one of the most polarizing figures who is loved by the right-wing activists but equally hated by those located at the other end of the spectrum. Of late, voices have evolved suspecting the credentials of Ngo. Last month, the Daily Beast carried out a probe on conservative news outlets like Newsmax and Washington Examiner that published Middle East hot takes from experts who were actually fake people pushing propaganda. As those who feel Ngo is unreliable enriched the Twitter campaign to unverify the man, DefendPDX, a collective of journalists, tweeted: Andy Ngo operates alter-egos so he can post a range of true opinions he knows would hurt his online ego.

So, who is Andy Ngo and what is it so controversial about him?

Ngo, who mocked the UnverifyAndyNgo trend on Twitter to ask What are they so afraid of?, is a conservative social media activist and journalist. The editor-at-large of The Post Millennial, a conservative news website in Canada, Ngo came to the limelight in June last year after facing the physical wrath of unidentified people, suspected as antifa protesters, while covering a counter protest to a Proud Boys march in Portland and for his alleged links with far-right groups. Son of immigrant parents from Vietnam, Ngo was born (1986) and raised in Portland and raised in a Buddhist family. He went to an evangelical Christian church in high school and became an atheist later. During his study days in the University of California, Ngo volunteered with AmericaCorps and graduated in 2009 with a degree in graphic designing. He struggled to get a job and worked as a photographer at a used car dealership besides doing various low-paying jobs. In 2015, Ngo started graduate studies in political science at Portland State University with research interests in secularism and political Islam.

While the Proud Boys were holding their rally in Portland, left-wing activists, including the local branch of the militant antifa group, came up with a counter protest. The two movements soon clashed and the incident that caught all the eyes was the attack on Ngo and he was reportedly sent to the hospital to overcome his injuries. In a video footage, it was seen how demonstrators poured milkshake on Ngo and hurled eggs at him, punched him and yelled at him. It looked like an act that was unprovoked and was carried out by people just because they didnt like Ngo. The man suffered a head injury.

But soon, both sides of the ideological spectrum tried to use the incident to suit their respective narratives. The conservative and mainstream media tried to establish that the attack on Ngo made it evident that left-wing violence was getting into a serious menace in the country. Texas Republican Senator Ted Cruz even sought an investigation into the Portland ruckus.

But the left-liberals were not ready to see Ngo as innocent. They said the mainstream media is portraying a wrong picture of the man of Vietnam descent. According to them, Ngo is a far-right sympathizer who had targeted the antifa members in the past. The sympathy for Ngo was only helping the right-wing smear campaign, they said. Press Secretary at the LGBTQ advocacy group Human Rights Campaign Charlotte Clymer had tweeted that violence is something that Ngo himself also wanted to see from the start.

Violence is completely wrong, and I find it sad and weak to allow a sniveling weasel like Andy Ngo to get under one's skin like this, but I'm also not going to pretend that this wasn't Ngo's goal from the start.

I mean... let's cut the shit here. This is what they do.

As race protests intensified in the US and even President Donald Trump accused the antifa protesters of inciting violence, Ngo filed a lawsuit worth $900k against the group in June for carrying out a campaign of terror and harassment against him. "Antifa is an openly extremist movement with the training and intent of destabilizing this country and overthrowing our Constitution," Ngo had said in a press conference. "The protection of foolish politicians and the media have emboldened this movement to carry out unprecedented terrorist attacks."

Ngo might not be a big name in the journalism fraternity but he is still a much discussed name. Quillette, the publication with which Ngo has been involved, is considered an intellectual dark web featuring aspects like anti-left ideologies and anti-political correctness. Ngos contribution to publicity lies in the fact that he has blended the ideological conservativeness with the tactic of a field reporter who works on the spot (conservative actor James Woods recently showered praise on Ngo to say that he is the one who is shining a light on domestic terrorism by antifa in Portland mocking American journalism). From Ground Zero, he releases content on social media to grant validation to his ideological leanings, demonizing the left and multiculturalism in the process.

To give an example, Ngo went to the UK to document the alleged threat the Muslim poeple there posed to the British society. He later wrote a piece A Visit to Islamic England claiming the country was being quietly gobbled up by fundamentalist Islam. He even showed a public safety board restricting alcohol as one to support his claim that Islam was indeed taking over England. Ngo is accused of twisting facts to play the narrative in a way that suits his ideological foundations and keeps on targeting the left and Muslim immigrants, conveniently ignorning that there are also cases of right-wing extremism happening around.

Many feel curious that being a man of non-American origin, why Ngo is still seen as pro-White? There is a striking story of evolution here. Ngo had his lessons from his familys not-so-happy past in Vietnam. His mother came from a middle class family and was thrown into a labor camp along with her family in her teens. His father was a police officer in a small coastal town and his job did not guarantee life. The family left for the US in 1978 to turn their fortunes around.

In my youth, my Asian-American or Vietnamese identity was really at the forefront of how I viewed myself," Ngo was once quoted as saying by a report in Oregon Public Broadcasting. I always felt, in a way, out of place growing up in the Pacific Northwest. At that time, I thought it was because of race. He found himself to be the only kid in his classes once but conceded that it was only twice that he experienced racism.

But for Ngo, a more shocking experience was waiting back home. When he traveled back to Vietnam for the first time, he was expecting that people there would welcome him. But it was not to be and that influenced Ngo.

When I arrived, I was thinking, This will feel like home. Ill finally be among my people, he said, adding: People looked at me, and they could tell right away that I was not native. My skin is really fair because I was raised in the US And so everywhere I went, people really stared at me. They made it very obvious. At first, I didn't quite know what was going on, so I asked my family there, and they were just like, Theyre not used to seeing somebody as white as you, as pale as you.

Ngo was in for more shock when he went to the rural parts of Vietnam to see his cousins. They pointed out his sexual orientation (he is a gay) and the experience thereafter changed his attitude towards race and politics. Why are you denying your parents the legacy of having children? The paradigm they were raised in was more about, You need to think about others, you cannot just be thinking about yourself. You have to think about your family, and by extension in a way your tribe, even if they wouldn't use that term, he told OPB.

Ngo said it was then when he started feeling more like an American.

Even though I am a sexual minority and Im a person of color, I come from a family who were refugees so I feel so lucky to be able to have been born and raised in this country. So yeah, when I see the American flag, I feel a sense of pride and honor of being part of that. And I regret that a lot of people see it as a symbol of violence that should be burnt, he said.

It is not unusual to see antifa supporters locking horns with Ngo often. The former group comprises typical black-clad activists who are radicals and who think radicalism is the most effective way to take on the far-right groups that are also supporters of Trump. It is not surprising to see these people attack Ngo who has smartly used journalistic techniques to expose the group which has a politically opposite belief system. But the problem lies in the fact that since both Ngo works in an individual capacity to validate his ideological leanings and the antifa members also do not have central command and are typically unanimous, there is a much higher chance of open physical fight when the two meet. Portland saw exactly that happening.

Link:

Who is Andy Ngo? From photographer at a used car dealership to one of America's most polarizing media figures - MEAWW

Can progenitor cells go further than gene therapy in retinal disorders? A biotech’s answer shines in PhIIb – Endpoints News

By the time the FDA approved Luxturna the pioneering gene therapy for an inherited retinal disease Henry Klassen had been researching and treating the group of diseases known as retinitis pigmentosa for more than 20 years.

Spark Therapeutics success there had not just inspired a $4.3 billion takeover by Roche, it had also emboldened other biotechs pursuing a therapy that would deliver one of the genes tied to different variations of the disorder. Nightstar Therapeutics subsequently scored its own buyout with Biogen, and MeiraGTx recently posted early but exciting data on its J&J-partnered program.

But Klassen went a different way.

Catching on the stem cell craze right at the turn of the millennium, he took inspiration from scientists who transplanted neural progenitor cells into the retina and developed a method to grow retinal progenitor cells instead as a therapy. Starting out as the director of stem cell research at the Childrens Hospital of Orange County, he continued the work at the University of California, Irvine, eventually spinning out a biotech dubbed jCyte in 2012.

Over the weekend jCyte reported positive Phase IIb results from what they call one of the largest studies ever conducted in RP, suggesting that patients on the treatment saw improved functional vision compared to the placebo group.

The credit to the gene therapies is that theyre actively trying to fix the gene underlying the problem. Thats very commendable, and were not doing that, Klassen told Endpoints News. But our treatment as it stands should have impact across a variety of different genotypes.

The study enrolled a total of 84 patients, of whom 74 were included for the final analysis. For each patient on the primary endpoint of best corrected visual acuity (measured with glasses on), the mean change from baseline to month 12 for the sham, low dose and high dose arms were +2.81, +2.96, and +7.43 letters, respectively.

In a post hoc analysis for a target subgroup, the difference was even more prominent: +1.85, -0.15, and +16.27 letters, respectively.

There was one serious adverse event in the low dose arm, but jCyte said the grade 3 ocular hypertension resolved with treatment and other side effects were generally minor.

CEO Paul Bresge noted that the target subgroup analysis was intended to hammer out the criteria they might use to recruit patients into Phase III which would likely have a similar design and use the same primary endpoint of BCVA, the gold standard in the context of FDA. The late-stage trial is slated for 2021.

We did enroll a very wide patient population into our Phase IIb, including patients that had vision anywhere from 20/80 to 20/800, just to learn which patients would potentially be the best responders, he said.

The target subgroup is characterized by having reliable fixation on the study eye, and a study eye that does not have significantly worse BCVA (15 letters) than the fellow eye.

He added that investigators also observed encouraging results with the secondary endpoints such as low light mobility, contrast sensitivity kinetic visual fields and a vision function questionnaire, although the data werent disclosed.

Typically people think about the disease as a narrowing of this peripheral vision in a very nice granular way, but thats actually not what happens, he said about the visual fields finding. What happens in the disease is that patients lose like islands of vision. So what were doing in our tests is actually measuring [] islands that the patients have at baseline, and then what were seeing after treatment is that the islands are expanding. Its similar to the way that one would track, lets say a tumor, in oncology of course were looking for the opposite effect. Were looking for the islands of vision to expand.

The therapy works primarily by preserving photoreceptors, Klassen posits, not by generating new ones. But what he thinks is happening is that photoreceptors are regenerating the outer segment if photoreceptors are radios, these would be the antenna thereby regaining some function.

That could position it as a treatment for a different stage of the disease than Sparks or Nightstars. Klassen, whos also researching retinal reconstruction using stem cells, is happy to not view it through the competitive lens.

If you look into the future, one could imagine that gene therapies will be most effective very early in the course of a disease before photoreceptors are lost, he said. Then as photoreceptors begin to be lost anyway, if that happens, then a therapy like ours would become extremely valuable. And if ours starts to lose power late in the course of a disease, maybe cell transplantation under the retina could have a role.

Read more:

Can progenitor cells go further than gene therapy in retinal disorders? A biotech's answer shines in PhIIb - Endpoints News

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD – GlobeNewswire

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD

Oxford, UK 31st July, 2020: Oxford Biomedica plc (LSE:OXB) (Oxford Biomedica or the Group), a leading gene and cell therapy group, announced today that it has signed a three year Clinical Supply Agreement (CSA) with a wholly-owned subsidiary of Axovant Gene Therapies Ltd. (Axovant) (Nasdaq: AXGT). The CSA builds on the worldwide license agreement signed between the two companies in June 2018 for the Parkinsons disease gene therapy program OXB-102, now called AXO-Lenti-PD.

Under the terms of the CSA, Oxford Biomedica will manufacture GMP batches for Axovant to support the ongoing and future clinical development of AXO-Lenti-PD, a clinical-stage gene therapy product to treat moderate to severe Parkinsons Disease based on Oxford Biomedicas LentiVector platform. Axovant is currently conducting a Phase 2 SUNRISE-PD trial with AXO-Lenti-PD. Dosing of all patients in the second cohort is completed with 6-month safety and efficacy data expected in the fourth quarter of 2020. OXB expects to manufacture AXO-Lenti-PD in its commercial-scale GMP manufacturing facilities including Oxbox in the UK, and additionally in other OXB GMP facilities as required to ensure security of supply.

John Dawson, Chief Executive Officer of Oxford Biomedica, said: This new Agreement builds upon our existing worldwide licensing agreement with Axovant and highlights the strengths of Oxford Biomedica's commercial GMP manufacturing capabilities. We are pleased with how the partnership is progressing and excited by the clinical progress to date. The agreement today signals our commitment to the efficient ongoing development of this much needed product for patients with Parkinsons disease.

We are now at a stage in the partnership where we can determine the manufacturing activities and infrastructure required to support the mid and late-stage development of AXO-Lenti-PD in a way which is compatible with later commercialisation and we look forward to this next phase of our partnership.

Pavan Cheruvu, Chief Executive Officer at Axovant Gene Therapies, said: This Agreement with Oxford Biomedica means that together we can continue to advance the development of AXO-Lenti-PD in Parkinsons disease. We are pleased to extend our partnership with Oxford Biomedica, a world leader in lentiviral vector development and manufacturing, as we scale-up AXO-Lenti-PD production to support our Phase 2 and Phase 3 clinical studies and enable commercialization of the product. This marks another mutual accomplishment for our Parkinsons disease program where we expect to enroll the first subject in a randomized, sham-controlled trial in 2021.

-Ends-

Oxford Biomedica plc

John Dawson, Chief Executive OfficerStuart Paynter, Chief Financial OfficerCatherine Isted, Head of Corporate Development & IR

T: +44 (0)1865 783 000T: +44 (0)1865 783 000T: +44 (0)1865 954 161 / E: ir@oxb.com

Consilium Strategic Communications

Mary-Jane Elliott/Matthew Neal

T: +44 (0)20 3709 5700

About Oxford BiomedicaOxford Biomedica (LSE:OXB) is a leading, fully integrated, gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford Biomedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology, CNS disorders, liver diseases and respiratory disease. The Group has also entered into a number of partnerships, including with Novartis, Bristol Myers Squibb, Sanofi, Axovant Gene Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium and Imperial Innovations, through which it has long-term economic interests in other potential gene and cell therapy products. Additionally the group has signed a Clinical and Commercial Supply Agreement with AstraZeneca for manufacture of the adeno based COVID-19 vaccine candidate, AZN1222. Oxford Biomedica is based across several locations in Oxfordshire, UK and employs more than 550 people. Further information is available atwww.oxb.com

About AXO-Lenti-PDAXO-Lenti-PD is an investigational gene therapy for the treatment of Parkinsons disease that is designed to deliver three genes (tyrosine hydroxylase, cyclohydrolase 1, and aromatic L-amino acid decarboxylase) via a single lentiviral vector to encode a set of critical enzymes required for dopamine synthesis, with the goal of reducing variability and restoring steady levels of dopamine in the brain. The investigational gene therapy aims to provide patient benefit for years following a single administration. The SUNRISE-PD Phase 2 trial is ongoing with dosing completed for all patients in cohort 2, with 6 month safety and efficacy data expected in Q4 2020. Axovant expects to dose the first patient in the Part B randomized, sham controlled study in 2021.

About Axovant Gene TherapiesAxovant Gene Therapies is a clinical-stage gene therapy company focused on developing a pipeline of innovative product candidates for debilitating neurodegenerative diseases. Our current pipeline of gene therapy candidates targets GM1 gangliosidosis, GM2 gangliosidosis (also known as Tay-Sachs disease and Sandhoff disease), and Parkinsons disease. Axovant is focused on accelerating product candidates into and through clinical trials with a team of experts in gene therapy development and through external partnerships with leading gene therapy organizations. For more information, visit http://www.axovant.com.

View post:

Oxford Biomedica Signs Three Year Clinical Supply Agreement with Axovant Gene Therapies for Manufacture and Supply of AXO-Lenti-PD - GlobeNewswire

Cell and Gene Therapy Market 2020 | Enormous Growth with Recent Trends & Demand By Top Vendors JW CreaGene, Vericel, Tego Sciences, CHIESI…

Cell and Gene Therapy Market In-depth Analysis 2020-2026

The report include a thorough study of the global Cell and Gene TherapyMarket. It has successfully pointed out the key factors that have substantial impact on theCell and Gene Therapy market. This report is a result of a well-planned research methodology. The methodology employed both primary and secondary research tools.

These tools aid the researchers to gather authentic data and arrive at a definite conclusion. The prevailing competitors in the global Cell and Gene TherapyMarket has also been pictured in the report, offering an opportunity to theCell and Gene Therapy market players to measuring system their performance.

Get a Sample Report with Latest Industry Trends @ https://www.marketresearchvision.com/request-sample/484986

The report has been prepared after studying the different parameters ruling the global Cell and Gene TherapyMarket and the forecast period has been estimated from 2020-2026. The forecast period is the time period when the key factors and parameters will help the market to flourish significantly. The estimated value of the market has been represented through a CAGR percentage. Additionally, the report represents the approximate revenue that can be generated over the forecast period. However, the report has also outlined the factors that can slowdown the growth of the global Cell and Gene TherapyMarket.

Key players in the global market covered, JW CreaGene, Vericel, Tego Sciences, CHIESI Farmaceutici, Spark Therapeutics, GC Pharma, MolMed, AnGes, Takeda Pharmaceutical Company, APAC Biotech, Gilead Sciences, Corestem, AVITA Medical, Novartis AG, JCR Pharmaceuticals, Dendreon, CO.DON, Medipost, Osiris Therapeutics, Amgen, Biosolution, CollPlant, Japan Tissue Engineering, Organogenesis, Orchard Therapeutics, Stempeutics Research, ,

on the basis of types, Cell Therapy, Gene Therapy, ,

on the basis of applications, Hospitals, Wound Care Centers, Cancer Care Centers, Ambulatory Surgical Centers, Others, ,

Click here to Get customization & check discount for the report

Key Drivers

The report includes the key driving forces prevailing in the global Cell and Gene TherapyMarket. This part of the report has been studied keeping in mind the political, economic, social, technological, geographical, and cultural scenario of the global Cell and Gene TherapyMarket. These factors can be projected to have their individual effects on the market, or they can have interconnected impacts. Besides, subtle change in the time framewithin which these factors are functioning might have ripple effects on the global Cell and Gene TherapyMarket.

Regional

Global Cell and Gene TherapyMarket has been segmented into Europe, the Americas, Asia Pacific, and the Middle East & Africa. This part of the report provides an exhaustive view of the regional scope existing in the global Cell and Gene TherapyMarket. The trends and preferences dominating each region has a direct impact on the industries. The report tries to exploit the trends and preferences prevailing in a region to offer the users with a clear picture of the business potential existing in that region.

Research Methodology

The primary research procedure conducted to arrive at the results includes panel of face to face interviews with industry experts and consumers. The secondary research procedure includes an intricate study of the scholarly journals and reports available online.

For More Details On this Report: @ https://www.marketresearchvision.com/reports/484986/Cell-and-Gene-Therapy-Market

if you have any special requirements, please contact us [emailprotected]

Excerpt from:

Cell and Gene Therapy Market 2020 | Enormous Growth with Recent Trends & Demand By Top Vendors JW CreaGene, Vericel, Tego Sciences, CHIESI...

Comprehensive Report on Gene Therapy for Ovarian Cancer Market 2020 | Trends, Growth Demand, Opportunities & Forecast To 2026 | Takara Bio, VBL…

Gene Therapy for Ovarian Cancer Market research is an intelligence report with meticulous efforts undertaken to study the right and valuable information. The data which has been looked upon is done considering both, the existing top players and the upcoming competitors. Business strategies of the key players and the new entering market industries are studied in detail. Well explained SWOT analysis, revenue share and contact information are shared in this report analysis.

Gene Therapy for Ovarian Cancer Market is growing at a High CAGR during the forecast period 2020-2026. The increasing interest of the individuals in this industry is that the major reason for the expansion of this market.

Get the PDF Sample Copy of This Report:

https://www.a2zmarketresearch.com/sample?reportId=265436

Top Key Players Profiled in This Report:

Takara Bio, VBL Therapeutics, CELSION, Targovax

The key questions answered in this report:

Various factors are responsible for the markets growth trajectory, which are studied at length in the report. In addition, the report lists down the restraints that are posing threat to the global Gene Therapy for Ovarian Cancer market. It also gauges the bargaining power of suppliers and buyers, threat from new entrants and product substitute, and the degree of competition prevailing in the market. The influence of the latest government guidelines is also analyzed in detail in the report. It studies the Gene Therapy for Ovarian Cancer markets trajectory between forecast periods.

Get up to 20% Discount on this Premium Report at:

https://www.a2zmarketresearch.com/discount?reportId=265436

Reasons for buying this report:

Table of Contents:

Global Gene Therapy for Ovarian Cancer Market Research Report

Chapter 1 Gene Therapy for Ovarian Cancer Market Overview

Chapter 2 Global Economic Impact on Industry

Chapter 3 Global Market Competition by Manufacturers

Chapter 4 Global Production, Revenue (Value) by Region

Chapter 5 Global Supply (Production), Consumption, Export, Import by Regions

Chapter 6 Global Production, Revenue (Value), Price Trend by Type

Chapter 7 Global Market Analysis by Application

Chapter 8 Manufacturing Cost Analysis

Chapter 9 Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter 10 Marketing Strategy Analysis, Distributors/Traders

Chapter 11 Market Effect Factors Analysis

Chapter 12 Global Gene Therapy for Ovarian Cancer Market Forecast

Buy Exclusive Report @:

https://www.a2zmarketresearch.com/buy?reportId=265436

If you have any special requirements, please let us know and we will offer you the report as you want.

View post:

Comprehensive Report on Gene Therapy for Ovarian Cancer Market 2020 | Trends, Growth Demand, Opportunities & Forecast To 2026 | Takara Bio, VBL...

T.J.s Forecast: A little chilly as we progress into our first week of August – KSN-TV

A cold front has been working through the region and were going to reap the rewards. Lowered humidity and cooler temps will hold thanks to northerly flow.

This will keep our temperatures well below average as we progress into the start of our first full week of August. Ill go as far as to say chilly for some of us.

Lows will be in the 50s across Western Kansas with Northern Kansas also falling below 60. In Wichita, well be pretty close but I think well stay near 60. Isolated showers and storms are possible as some of this cold front stalls to our west.

This boundary is allowing the winds to switch to more of a SE direction. Because of that lift or convergence, we could see more storms develop in Colorado later on this evening. Some of these could work into Kansas late this evening into the overnight.

The bulk of the severe activity will remain west of us but we could see a rogue stronger storm with gusty winds and smaller hail possible. Monday will remain mild with highs in the 80s for many of us with some spots possibly still in the upper 70s.

That stalled front will hang out, continuing to be a focal point for more storms as we head through Monday. A few could linger early in the day but they will be widely scattered.

A better chance arrives late Tuesday into Wednesday. Winds will be out of the south to the southeast for all of us at that point which will help bring more moisture and warmth our way. Those 2 ingredients will fuel the potential for storms with some isolated severe storms on the table Tuesday.

Moisture will linger into Wednesday which looks to keep us just a little more stable. The severe threat will still need to be monitored as it does for the latter half of the workweek. NW flow aloft will keep impulses tracking into Kansas.

High pressure does try and build in by the weekend meaning drier and much hotter conditions. Highs will surge back into the mid and upper 90s by this time next weekend with a good deal of sunshine.

Have a great night!

-T.J.

Read the original here:

T.J.s Forecast: A little chilly as we progress into our first week of August - KSN-TV

Tyler Perry Gives Progress Report On Producing His Shows During Pandemic, Shares His Hope For The Industry & The Country – Deadline

Tyler Perrywas one of the first Hollywood producers to come upwith a comprehensive plan to safely restart TV production back in April. Now he is the first to have completed a full season of a primetime scripted series filmed during the pandemic using COVID-19 safety protocols. It is Season 2 of his BET show Sistas, which recently wrapped production at the Tyler Perry Studios in Atlanta and will be ready for a fall debut.

In the break between finishing Sistas on July 25 and starting Season 2 of BETs The Oval, whose cast members will begin arriving at the studio Thursday, Perry discussed with Deadline how filming and testing went; addressed challenges they faced; and what advice he has for producers who are apprehensive about heading back into production before a coronavirus vaccine is widely available, outlining daily testing or quarantine bubbles as crucial to a successful restart.

As we have reported, Perry employs a quarantine bubble model, sequestering cast and crew on the lot for the duration of a shoot. In May, he sent out a 30-page document to his casts outlining the plan in great detail.

Perry said he and his team followed that document to the letter, and it worked. (You can watch a behind-the-scenes video of the process and the accommodations on Sistas below.) He will use the exact same protocols for The Oval and two other shows he has lined up at the studio one after the other through September: Bruh and Ruthless, both for BET+.

All of the hard work and months of planning paid off. Production went extremely well on the second season of Sistas, and now were preparing for The Oval, said Michelle Sneed, president of production and development at Tyler Perry Studios. Of course, there is always a learning curve when embarking on a new project and even more so when filming it in the middle of a pandemic. However, one of the most valuable lessons I learned is to trust the process and the people you have in place to do their job.

There were 360 people cast, crew and 10 extras inside the bubble who worked on Season 2 of Sistas for the duration of the shoot. That was down 80-100 people from the regular production team that worked on Season 1 as Perry had to scale back because of the amount of housing available on the premises.

However, my crew stepped up and they were amazing, Perry said.

Still, production was intense. We were shooting an enormous amount of pages a day, he said. Moves that wouldve taken 10-15 minutes took 45, but it was fine. It flowed, it completely flowed.

Actors were flown in from New York and Los Angeles on Perrys private plane.

We checked in 160 on Thursday [July 9] with the actors, four days before they started working. They were tested before they got on the plane, Perry said.

Everybody cast and crew was tested on that Monday [July 13]. The crew check-in was Tuesday, July 14, with everyone staying in their rooms until test results came back.

We had four positives in our initial check-in before anyone was allowed to leave their room, Perry said. We had those people leave and got them the help they needed. The positive tests did not involve cast; two of them were extras, two were crew.

Everyone then was tested every four days for the duration of the shoot with no positive results as the quarantine bubble held up. The production used PCR tests, which are the most accurate available so far. All through pre-production, test results were coming the next day. But then came the nationwide spike in cases, and test results began to take longer, 36-48 hours, which led to a delay in the start of production pushed from July 14 to July 15. That issue since has been resolved. The labs that we are using now give the results back within 24 hours, Perry said.

Perry admits that he was worried heading into the endeavor.

My biggest concern was, I have several crew members who have preexisting conditions that I asked personally to sit this one out but they said no, they wanted to work, they needed to work, Perry said. I couldnt legally stop them from working, so my biggest concern was making sure that they were safe and that the actors who did not wear masks were safe. Because masks one hundred percent help cut down on the spread. Every time an actor had a mask off, and every time I looked at the people with preexisting conditions, they were my biggest concern.

Everyone on the set of Perrys shows is required to wear a mask except for actors when they are filming scenes.

In April, Emmy-nominated hairstylist Charles Gregory Ross, who had worked with Perry in the past, died of COVID-19. His passing had a profound impact of Perry and his approach to resuming production. It also helps him understand other producers who are apprehensive about getting their shows up and running amid the pandemic.

After losing a crew member to COVID that was on another production at the very beginning of this thing, clearly I understand the nervousness, I understand the trepidation, and they should enter with extreme caution, Perry said. But I tell you, if you cant test everyone every day, I dont know how you do this unless its a quarantine bubble. I dont know another way, because COVID could be among you and spreading and you not know it.

As of now, only Perrys shows are filming at his studio one at a time. But with his Camp Quarantine model showing results, he is ready to open the lot to outside productions.

There is still another 200 acres of open land, several other camps can be set up here just like the one we set up; camps can be set up in no time we set up ours in a month, month and a half, Perry said. There are many, many more housing opportunities for other camps for sure.

Already, there is interest. I have had several phone calls when it will be available and what we could do; there are some conversations that are happening, Perry said.

He admits that he did not have to jump in, develop the safety guidelines and start production amid the pandemic, but he felt an obligation to do it.

I could just go and sit somewhere and wait for a vaccine but what wouldve happen with all of those people and their lives and their livelihoods if I didnt do this? he said. The level of thank yous that I got from the crew privately as I was passing through because Im there with them the entire time, Im going to the food truck or going to grab a drink at the truck bar they tell me just how much they appreciate having the opportunity to work and work safely.

Perry is prepared to use the current production setup for months or even years.

We are set up for the long haul, we could be here for a year and a half, two years, five years if we needed to, he said. But my hope is that there is a vaccine by this time next year. I know the hope is it will be by the end of the year, but even if its by the end of the year, by the time they ramped up production and by the time it got to the masses, to say another year is safe.

Along with his work on restarting production at his studio, over the last few months Perry has been active in his community and a leading voice of the Black Lives Matter movement. In April, he donated $21,000 to 42 out-of-work servers $500 each at Houstons on Northside Parkway, a favorite restaurant of his. A few weeks later, Perry anonymously picked up the tabs at 44 Atlanta-area Krogers during the stores designated shopping hour for seniors and at-risk patrons. He did the same for 29 Winn-Dixies in his hometown of New Orleans.

Following the death of George Floyd, which triggered nationwide protests, Perry wrote a essay on racial injustice, featured on the cover of People. He provided travel for Rev. Al Sharpton, Eric Garners mother Gwen Carr and members of Floyds family to Floyds funeral. He also paid all funeral expenses for Rayshard Brooks, who was fatally shot by an Atlanta police officer, and for Secoriea Turner, an 8-year-old girl who was fatally struck by gunfire.

Last week, Perry, donated 1,000 Kroger gift cards to Southeast Atlanta residents, teaming with the Atlanta Police Department to distribute the $50 cards.

What is happening in the country right now with all the protests, and with even Secoriea, the 8-year-old killed in Atlanta. All of that has been on my mind, Perry said. So when I gave those gift cards to the neighborhood around the studio and asked the police to pass them out, my hope was to bring some unity in the community, to bring understanding that all cops are not bad cops and we need them, as well as all Black people are not bad people, and that kind of mentality and that kind of thinking that is blanketed is wrong. My hope is that everybody would come from their corners and just have some conversations. Thats my hope for the country; lets have some conversations that we could at least hear each other.

As for the industry, my hope is that the industry could get back to work, Perry said. There are so many people who need to work. Its my hope that everybody could go back to work. I dont know how that happens without daily testing or quarantine bubbles.

See more here:

Tyler Perry Gives Progress Report On Producing His Shows During Pandemic, Shares His Hope For The Industry & The Country - Deadline

Melbourne is a Case Study in Navigating a Second Wave of Coronavirus – The New York Times

Australias second-largest city, Melbourne, is grappling with a spiraling coronavirus outbreak that has led to a lockdown with some of the toughest restrictions in the world offering a preview of what many urban dwellers elsewhere could confront in coming weeks and months.

The new lockdown is the product of early success; the country thought it had the virus beat in June. But there was a breakdown in the quarantine program for hotels. Returning travelers passed the virus to hotel security guards in Melbourne, who carried the contagion home.

Even after masks became mandatory in the city two weeks ago, the spread continued. And now, as officials try to break the chain of infections, Melbourne is being reshaped by sweeping enforcement and fine print. A confounding matrix of hefty fines for disobedience to the lockdown and minor exceptions for everything from romantic partners to home building has led to silenced streets and endless versions of the question: So, wait, can I ____?

Restaurant owners are wondering about food delivery after an 8 p.m. curfew began on Sunday night. Teenagers are asking if their boyfriends and girlfriends count as essential partners. Can animal shelter volunteers walk dogs at night? Are house cleaners essential for those struggling with their mental health? Can people who have been tested exercise outside?

This is such a weird, scary, bizarro time that we live in, said Tessethia Von Tessle Roberts, 25, a student in Melbourne who admits to having hit a breaking point a few days ago, when her washing machine broke.

Our health care workers are hustling around the clock to keep us alive, she said. Our politicians are as scared as we are, but they have to pretend like they have a better idea than we do of whats going to happen next.

Pandemic lockdowns, never easy, are getting ever more confusing and contentious as they evolve in the face of second and third rounds of outbreaks that have exhausted both officials and residents. With success against the virus as fleeting as the breeze, the new waves of restrictions feel to many like a bombing raid that just wont end.

For some places, risk calculations can change overnight. In Hong Kong, officials banned daytime dining in restaurants last month, only to reverse themselves a day later after an outcry. Schools in some cities are opening and closing like screen doors in summer.

In many areas where the virus has retreated and then resurged, the future looks like a long, complicated haul. Leaders are reaching for their own metaphors to try to explain it.

In California, Gov. Gavin Newsom has compared his opening and shutting of businesses to a dimmer switch. Dan Andrews, the premier in Victoria, the state of which Melbourne is the capital, has repeatedly referred to pilot light mode for industries like construction and meatpacking, which have been ordered to temporarily reduce their work forces.

Whatever the metaphor, the situation is bleak.

In Melbourne, a city of five million that is considered a capital of food and culture, the pandemic has come raging back even after a so-called Stage 3 lockdown began in early July until recently the highest level of restrictions.

Officials have been flummoxed at every turn by the persistent complacency of just enough people to let the virus thrive and multiply.

Traffic data showed people driving more in July than they had during the first Stage 3 lockdown, in March and April. Even worse, almost nine out of 10 people with Covid-19 had not been tested or isolated when they first felt sick, Mr. Andrews, the states top leader, said in late July. And 53 percent had not quarantined while waiting for their test results.

That means people have felt unwell and just gone about their business, Mr. Andrews said.

Sounding the alarm, he made face masks mandatory the next day, on July 22.

Still, infections have continued to rise. They peaked at 753 new cases on July 30, and have hovered around 500 a day ever since, with the death toll in Victoria now standing at 147, after 11 deaths were recorded on Monday.

Those figures, while far less troublesome than those in the United States, have paved the way for a Stage 4 lockdown what officials are calling a shock and awe attack on the virus that will last at least six weeks.

Overwhelming force, with precision, seems to be the goal. The chief modelers of the pandemic response in Australia have found that the virus can be suppressed only if more than 70 percent of the population abides by social distancing guidelines and other public health rules.

Mr. Andrews said the new restrictions would take 250,000 more people out of their routines, in the hopes of reaching the necessary threshold.

So retail stores will be closed. Schools will return to at-home instruction. Restaurants will be takeout or delivery only. Child-care centers will be available only for permitted workers.

Those restrictions are already well understood. The rules requiring more explanation are tied to the curfew and industries that have to cut back.

Large-scale construction projects of more than three stories, for example, will have to reduce their on-site work force by 75 percent, and workers will not be able to work at more than one location. Small-scale construction cannot have more than five workers.

All of which sounds clear. But does a bathroom renovation, for example, amount to home building in an apartment with one bathroom? And what about fixing things that break, like Ms. Von Tessle Robertss washing machine?

Some businesses, like cleaning services, are already emailing customers to say they think they can do some work, for people who pay through welfare or who need help for mental health reasons. But, like many others, they are still seeking official clarification.

Mr. Andrews, a Labor politician sometimes described as awkward and paternal, has become the dad everyone needs answers from. He now oversees, under the lockdown rules, what may be the countrys most intrusive bureaucracy since its days as a penal colony.

Updated August 4, 2020

On Tuesday, he answered questions from reporters about dog-walking (allowed after curfew, sort of, only near home) and other subjects of great confusion at a news conference in Melbourne.

Thanking those who complied with the new rules and scolding those who did not, he announced that no one in self-isolation would now be allowed to exercise outdoors. A door-knocking campaign to check in on 3,000 people who had Covid-19 found that 800 of them were not at home.

All 800 have been referred to the Victoria police for investigation. The fine for violators going forward, he said, will be 4,957 Australian dollars, $3,532.

Working, even legally, will also become trickier. Other than, say, hospital workers with formal identification, everyone traveling for a job deemed essential during the lockdown must carry a formal document a work permit signed by the employer and employee.

For Cara Devine, who works at a wine store that closes at 8 p.m., that means carrying a government form with her everywhere, and hoping that the police recognize her task as essential when she heads home after the curfew. But she also worried about the Uber drivers who take her back and forth.

Even before the newest restrictions, Ive had two Uber drivers being really late picking up from the shop because they got stopped by the police, taking about an hour out of their work time, she said.

The police are already confronting opposition. On at least four occasions in the last week, they reported having to smash the windows of cars and pull people out after they refused to provide a name and address at a police checkpoint. The Victoria police commissioner, Shane Patton, said a 38-year-old woman had also been charged with assault after attacking a police officer who had stopped her for not wearing a face mask.

Some criminologists are questioning whether the harsher enforcement will help. Mostly, though, Melburnians are just trying to endure.

Walking to get groceries, Peter Barnes, 56, said he welcomed the stricter rules, though he admitted his city was starting to feel like George Orwells 1984, with the heavy hand of the state around every corner.

Those focused solely on the economics, he said, should remember the obvious: You cant hire a corpse. Very bad employment prospects for people who are dead.

By Monday night, the city seemed to be in listening mode. The streets were emptying out, silent in hibernation.

Its like a Sunday in the 1950s, said Mark Rubbo, the owner of Readings, Melbournes largest independent bookstore. He also noted that people were stocking up again on books through online orders, with a memoir called The Happiest Man on Earth, about a Holocaust survivor, becoming a runaway hit.

Ms. Von Tessle Roberts has found another solution, perhaps just as likely to grow in popularity: Stand on your front porch and scream. Thats the name she has given to an event she posted on Facebook, set for Friday at 7 p.m. By Tuesday afternoon, 70,000 people had expressed an interest in joining her collective shout in anguish.

Yelling is great, she said. Its less dehydrating than crying.

Besha Rodell and Yan Zhuang contributed reporting from Melbourne, and Livia Albeck-Ripka from Cairns, Australia.

See original here:

Melbourne is a Case Study in Navigating a Second Wave of Coronavirus - The New York Times

California Coronavirus Update: Governor Gavin Newsom Warns COVID Could Impact Labor Day, Halloween And The Holidays – Deadline

California Gov. Gavin Newsom held a coronavirus press conference Monday and highlighted some good news. He also issued a warning about the states future with respect to COVID-19.

Newsom announced a total of 5,719 new coronavirus cases in the state for a total of 514,901 confirmed cases since the pandemic began. Thats a much lower daily number than some of the record-setting totals seen last week.

The overall trendis showing a decrease from where we were over a week ago, said Newsom. But one week does not make the kind of trend that gives us confidence to generate headlines. We are looking forward to that and need to see another few weeks of this kind of data to come in to feel more confident about where we are as a state.

The rate of positive tests over the last 14 days is 7.0 percent. Thats down from 7.4 about two weeks ago.

On Monday, there were 6,383 coronavirus patients in hospitals. Thats down from more than 8,800 on July 21. Likewise ICU beds; the number now occupied by COVID-19 patients has fallen below 2,000.

The good news is we do feel confident about our critical care capacity, pointed out the governor.

Newsom announced 32 new deaths, resulting in a total of 9,388 people lost to the pandemic. Thirty-two is a lower number than in the past[but] were likely to see those numbers remain stubbornly high over the next few days and weeks.

These are just a few days worth of results, warned the governor.

Weve seen some stabilization in most parts of the state, said Newsom. At the same time, we can quickly find ourselves back to where we were just a few weeks ago, a month ago, with significant increases if we do not maintain our vigilance.

This virus is not going away, he warned. Its not just going to take Labor Day off. Its not going to take Halloween off. Or the holidays off.

Until we have quality therapeutics, until we have a vaccine, we are going to be living with this virus, predicted Newsom.

We anticipate the second wave in the fall, he said. And that second wave also challenged byflu season on top of COVID-19.

Watch Newsoms new conference below.

More here:

California Coronavirus Update: Governor Gavin Newsom Warns COVID Could Impact Labor Day, Halloween And The Holidays - Deadline

Safety is top of mind as US develops coronavirus vaccine – US Embassy in Georgia

America, along with the rest of the world, is working swiftly to develop a vaccine against SARS-CoV-2, the new coronavirus responsible for COVID-19.

Many people are pinning their hopes on the development of a safe and effective vaccine for COVID-19 that can stop the spread of the virus. Through itsOperation Warp Speed initiative, the Trump administration is investing billions of dollars to accelerate efforts in the U.S. to develop, manufacture and distribute such vaccines.

But despite the efforts to work quickly, safety remains the top priority of researchers in the U.S.

We are moving as quickly as we can to shorten the timelines to get a vaccine to the public, but we will not compromise one iota the multiple safety checks and safety processes that we have always had in place for vaccine development and testing, says Kayvon Modjarrad, director for emerging infectious diseases at the U.S. Armys Walter Reed Army Institute of Research, which is working to develop a vaccine for COVID-19. We cannot and will not take any shortcuts when it comes to safety assessments of the vaccines we are advancing.

The FDA [U.S. Food and Drug Administration] will only approve or make available a COVID-19 vaccine if we determine that it meets the high standards that people have come to expect of the agency, said Peter Marks, director of the FDAs Center for Biologics Evaluation and Research.

Vaccines typically take years to develop, and extensive testing is built into the process. In the U.S., promising vaccines developed in the lab move on to animal studies, followed by human studies called clinical trials. The FDA sets guidelines for the three phases of clinical trials, with each phase increasing in population size. Phase 3 clinical trials, for example, typically involve thousands of volunteers receiving the test vaccine.

If the clinical trials show that the vaccine is effective without harmful side effects, the vaccine manufacturer can apply for FDA approval to publicly administer it. Even after the vaccine is in widespread use, the federal government continually monitors it for adverse effects.

History shows the potential risks associated with vaccine development. A polio vaccine developed by renowned scientist Jonas Salk was licensed for public use in 1955, but a production error caused some batches of the vaccine to contain the live virus. The incident led to increased quality-control measures in the U.S., to ensure safe immunization of children.

Peoples lives are too important for us to cut corners on the safety side of things.Robert Hopkins, chair of the National Vaccine Advisory Committee

Today, the FDAs Center for Biologics Evaluation and Research oversees vaccine safety and reviews and licenses vaccine candidates in the U.S.

David Jones, a professor of the history of science at Harvard University, says vaccine development is inherently safer than in the past. Rather than live virus, most vaccines contain either an inactivated form of the virus or a specific protein of the virus that is used to trigger the bodys immune response.

New candidate COVID-19 vaccines, including those in development by Moderna and Pfizer/BioNtech, are exploring new technologies using the viruss genetic code.

Nevertheless, safety is critical. Theres a tremendous amount at stake, says Jones. If a vaccine is developed without safety at the forefront of the process, it could harm peoples health and create a loss of trust. That could potentially decrease vaccination rates for polio, measles and everything else, says Jones.

The U.S. is working to shorten the path to a COVID-19 vaccine without compromising safety, says Robert Hopkins, chair of the National Vaccine Advisory Committee, which advises the U.S. Department of Health and Human Services National Vaccine Program on development and safety.

Whats being done with Operation Warp Speed and a lot of our current vaccine trials is that were taking some of those [usual] steps and instead of doing them one after the other, were doing some of them in parallel, says Hopkins. We are doing things in a slightly different sequence in order to get to the end point more rapidly, but that doesnt mean were cutting out any of the steps when it comes to assessing safety and efficacy. Peoples lives are too important for us to cut corners on the safety side of things.

Modjarrad, of the Walter Reed Army Institute of Research, says that manufacturers typically wait for all the clinical studies and approvals from the FDA to be complete before making large doses of the vaccine. That adds on months, if not years, to the timeline, he says. Not so with Operation Warp Speed, which is partnering with the private sector to scale up manufacturing of multiple candidate COVID-19 vaccines.

By not waiting for the clinical studies to be completed to make the large doses of vaccine, we will have vaccine ready for large populations the day it is approved by the FDA, Modjarrad says. (Note: If it is not approved, the doses will not be used.)

Whats more, he says, our expertise with coronaviruses; our experts in immunology, structural biology and virology; our manufacturing facility and clinical trials center have all come together to compress the timeline of vaccine development. Nowhere along the way have we skipped any steps in ensuring, assessing and reassessing safety processes.

I cannot stress enough how controlled and regulated a process vaccine development is when it comes to safety, Modjarrad continues. That is the prime objective, safety, when it comes to the development of these vaccines.

Freelance writer Linda Wang wrote this article.

Go here to read the rest:

Safety is top of mind as US develops coronavirus vaccine - US Embassy in Georgia

In Nashville, fewer coronavirus infections and a glimmer of hope – Tennessean

About a month after closing bars and mandating masks, Nashville officials say the city has made promising but fragile progress against the spread of coronavirus, offering a rare sign of hope in a state where the pandemic is otherwise growing.

The average number of new daily infections in Nashville has dropped 28% percent in just the past week. Hospitalizations, which climbed throughoutmuch of July, have begun to flatten. Fatalities remain low.

The steps we took a month ago, mandating masks, going to a modified Phase Two and closing bars, are working, said Dr. Alex Jahangir, head of the Nashville coronavirus task force, on Tuesday.We are seeing our metrics improve, but we are not out of the woods yet. And most of you are doing your part.

Dr. Michael Caldwell, Director of the Metro Public Health Department, reminds people to wear masks on Lower Broadway in Nashville, Tenn., Friday, July 31, 2020.(Photo: Andrew Nelles / The Tennessean)

Nashville made this progress despite a worsening statewide outbreak and an impasse on Lower Broadway, the heart of the citys entertainment district, where unmasked crowds gather in brazen defiance of public health orders. City officials have become increasingly desperate to rein in Broadway but have largely failed to do so.

CORONAVIRUS: Nashville officials signal intent to prosecute organizers of Fashion House party

Mayor John Cooper said Tuesday the city may soon try "different strategies on Broadway and conceded that closing the street altogether was a possibility. Cooper suggested Nashville is making progress, despite defiance on Broadway, because thosecrowds are largely composed of tourists.

The fact is that a lot of people on Lower Broadway may be testing positive and not showing up in our numbers. They dont live here Cooper said. We dont want COVID-19 to show up in these folks home communities either.

As of Tuesday, Nashville had recorded 21,879 residents with coronavirus, including about 3,500 active infections, 700 total hospitalizations and 199 deaths. Average daily infections peaked in July at more than 400 and have since fallen to about 250. More than 220 people were actively hospitalized two weeks ago, but that count has since fallen to 170. Test positivity rates, as calculated by the city, have fallen to their lowest point since June.

The slowing of infections in Nashville is a likely result of themandatingmasks on June 28 and closingbars on July 3. The city followed up two weeks later by ordering restaurants to shut their doors at 10 p.m. in an effort to limit restaurants that essentially became bars after dark.

Cooper said these decisions were recently validated by the White House coronavirus task force, which recommended similar precautions statewide. Gov. Bill Lee gave county mayors the authority to require masks but hasn't issued a statewide mandate and rejected a White House recommendation to close bars.

Although the virus is slowing in Nashville, the story is not the same statewide. Tennessee infections and deaths increased throughout most of July, and average hospitalizations reached record levels just last week. Experts warn the virus is moving away from major citieslike Nashville and Memphisand into smaller cities and rural areas that have less hospitals and public health resources to combat an outbreak.

Brett Kelman is the health care reporter for The Tennessean. He can be reached at 615-259-8287 or at brett.kelman@tennessean.com. Follow him on Twitter at @brettkelman.

Read or Share this story: https://www.tennessean.com/story/news/2020/08/04/nashville-fewer-coronavirus-infections-and-glimmer-hope/5573770002/

More here:

In Nashville, fewer coronavirus infections and a glimmer of hope - Tennessean

Can Humans Give Coronavirus to Bats, and Other Wildlife? – The New York Times

Many people worry about bats as a source of viruses, including the one that has caused a worldwide pandemic. But another question is surfacing: Could humans pass the novel coronavirus to wildlife, specifically North American bats?

It may seem like the last pandemic worry right now, far down the line after concerns about getting sick and staying employed. But as the spread of the novel coronavirus has made clear, the more careful we are about viruses passing among species, the better off we are.

The scientific consensus is that the virus originated in bats in China or neighboring countries. A recent paper tracing the genetic lineage of the novel virus found evidence that it probably evolved in bats into its current form. The researchers also concluded that either this coronavirus or others that could make the jump to humans are likely present in bat populations now we just havent found them yet.

So why worry about infecting new bats with the current virus? The federal government considers it a legitimate concern both for bat populations, which have been devastated by a fungal disease called white-nose syndrome, and for humans, given potential problems down the road.

The U.S. Geological Survey and the Fish and Wildlife Service, two agencies involved in research on bats, took the issue seriously enough to convene a panel of 12 experts to analyze the likelihood of human-to-bat transmission of the virus, SARS-CoV-2, in North America.

Another team of scientists, mostly from the two agencies, assessed the expert opinions and issued a report in June. They concluded that there is some risk, although how much is hard to pin down. Taking precautions, like wearing masks, gloves and protective clothing, could significantly cut it down.

Kevin Olival, a vice president for research at EcoHealth Alliance, an independent group and an author of the report, said that as the virus began to spread around the globe, there was a real concern that not only North American but wildlife populations all over the world could be exposed.

While the group studied interactions between North American bats and scientific researchers, Dr. Olival said wildlife-control workers and people who rehabilitate injured bats, for example, may come into contact with bats even more than researchers do.

Evaluating risk meant trying to cope with unknowns piled on unknowns: the risk of an infected research scientist or wildlife worker encountering bats; the risk of the bats becoming infected in that situation; the risk of an infected bat passing the virus onto other bats so that the virus becomes established in the population.

The authors of the paper concluded there was a risk of humans infecting bats with the novel coronavirus. How much risk? You might say little, or small, or unknown, but this report is from two federal agencies, so it describes the risk as non-negligible.

Although the issue of how bat researchers should conduct their work may seem narrow, the potential consequences are broad. The report notes that if SARS-CoV-2 became established in North American bats, it would allow the virus to keep propagating in animals even if it didnt cause disease. And the virus could potentially spill back over to humans after this pandemic is contained.

Another concern involves how readily the coronavirus might spread from bats to other kinds of wildlife or domestic animals, including pets. Scientists have already shown that domestic cats and big cats can become infected, and domestic cats can infect each other. Ferrets are easily infected, as are minks. On the suspicion that they may be passing the disease to people, Spain and the Netherlands have slaughtered thousands of minks at fur farms.

A small number of infected pets has gotten a good deal of publicity. But public health authorities like the Centers for Disease Control and Prevention have said that, although information is limited, the risk of pets spreading the virus to people is low. They do recommend that any person who has Covid-19 take the same precautions with their pets that they would with human family members. National Geographic reported Thursday that the first U. S. dog known to have tested positive for SARS-CoV-2, had died. The dog, Buddy, apparently had lymphoma.

Updated August 4, 2020

As to the susceptibility of North American bats, Dr. Olival was not aware of any published work on whether they can be infected with the virus. Researchers in Hong Kong have reported that in a lab the coronavirus infected the intestinal cells of Chinese rufous horseshoe bats. A report this month in The Lancet found that fruit bats could become infected with the virus.

Beyond bats, Dr. Olival said that scientists should be concerned about how they conduct research on wildlife in general and consider what precautions to take to avoid potentially infecting one species or another. One step, he said, would be evaluating research goals to weigh what level of contact would be necessary.

In some cases, he said, observation and data recording could be done without handling animals. If not, gloves and other precautions make sense, although some old-school researchers have balked at the suggestions, he said.

He said his group continues to recommend, the highest level of personal protective equipment when you work with wildlife, because its not just a risk that you will pick up something from the wildlife, but that you dont give something back to them.

He acknowledged that research precautions with wildlife will have a very small effect, given the greater number of people who hunt wildlife or come into contact in other ways. Education efforts are underway to try to change some of those practices; in addition that, he said, researchers should set some kind of standard.

Read this article:

Can Humans Give Coronavirus to Bats, and Other Wildlife? - The New York Times

LSU’s Travez Moore issues warning after coronavirus experience; virus ‘is real’ – The Advocate

LSU senior linebacker Travez Moore shared his experience with coronavirus on Twitter on Tuesday morning. He is thought to be the first Tigers football player to speak publicly about his experience with the virus during a pandemic that has shut down large parts of the country and altered the direction of every sport.

The 6-foot-4 Bastrop High graduate said he lost significant weight, dropping from 256 pounds to 229. He said he lost his appetite and had difficulty breathing. He lost senses of taste and smell, both of which are symptoms of the virus.

"Bro coronavirus is real," wrote Moore, who recorded three tackles, a half tackle for loss and half a sack in 2019.

Multiple LSU football players tested positive for coronavirus when the team first reported to campus on June 8. The total number of cases began with a group of five to six players, a source said, andSports Illustrated reportedat least 30 of LSU's 115 players were quarantined because they either tested positive or had contact with a player who tested positive.

Orgeron later said that reported numberwas too high and that the team's case numbers are "way down."At last week's Baton Rouge Rotary Club meeting, Orgeron said "I think we have two guys right now," that have tested positive for the virus.

Health and safety concerns have been addressed by such leadership. The Southeastern Conference announced in mid-July that players who opted to sit out the fall season would not lose their scholarships an action recommended by the league's athletic directors and approved unanimously by the league's presidents and chancellors.

Orgeron said at the Rotary Club meeting that no LSU players have chosen to sit out this season because of health concerns.

"None of our players have talked about that," Orgeron said. "I know that they have the option. Our players are eager to play. These guys are elite. These guys want to win championships. They believe in each other. I don't expect much of that to happen."

Success! An email has been sent with a link to confirm list signup.

Error! There was an error processing your request.

Continued here:

LSU's Travez Moore issues warning after coronavirus experience; virus 'is real' - The Advocate

Texas Widow Blames President Trump, Gov. Abbott In Husbands Obituary For Coronavirus Death: Shame On All Of You – CBS Dallas / Fort Worth

FORT WORTH (CBSDFW.COM) The widow of a Texas man who died of COVID-19, blamed President Donald Trump and Gov. Greg Abbott in her husbands obituary for his needless death.

David Nagys obituary calls out President Trump and Gov. Abbott in his obituary published in the Jefferson Jimplecute on July 30.

Dave did everything he was supposed to do, but you did not, his widow Stacey Nagy wrote. Shame on all of you, and may Karma find you all!

Houston Chronicle web producer Jordan Ray tweeted an image of the newspaper obituary.

David Nagy was 79 and died in the intensive care unit at Christus Good Shepherd Hospital in Longview, Texas on July 22.

He suffered greatly from the ravages of the COVID-19 virus and the separation from his much loved family who were not allowed at his bedside, the obituary said.

He left being his wife, five children and numerous grandchildren and great-grandchildren.

David Nagys family members blame his death and the deaths of all other innocent people, on Trump, Abbott and all of the other politicians who did not take this pandemic seriously and were more concerned with their popularity and votes than lives, his widow wrote. Also to blame are the many ignorant, self-centered and selfish people who refused to follow the advice of the medical professionals, believing their right not to wear a mask was more important than killing innocent people.

Go here to see the original:

Texas Widow Blames President Trump, Gov. Abbott In Husbands Obituary For Coronavirus Death: Shame On All Of You - CBS Dallas / Fort Worth

Salvaging the Security Council’s coronavirus response – World – ReliefWeb

On 1 July, the UN Security Council adopted a resolution calling for a global COVID-19 ceasefire, as the Secretary-General had urged months earlier. Their appeal has fallen flat. Council members should use their August downtime to look at how it might still do some good.

Just over a month ago, on 1 July, the UN Security Council passed a resolution addressing COVID-19 that looked hugely ambitious on paper. Echoing an earlier initiative by UN Secretary-General Antnio Guterres, Resolution 2532 centres on a call for all parties to armed conflicts to engage immediately in a durable humanitarian pause lasting 90 days in response to the pandemic. This document will earn a footnote in histories of the UN, as it is the first time the Council has advocated such a global ceasefire. But beyond that, it seems unlikely to be widely remembered, as its practical effects have been all but nil. Only one conflict party Colombias National Liberation Army or ELN has explicitly cited the resolution in offering to suspend hostilities and the Colombian government rejected the overture. Elsewhere, governments and armed groups engaged in fighting have shown no sign of heeding the Councils call.

Resolution 2532s lack of impact to date is disappointing in part because, earlier in the pandemic, it briefly looked like the Council could lend momentum to Secretary-General Guterres aspirational but worthy ceasefire effort, and so play a part in the global response to COVID-19. Guterres first floated the ceasefire idea in late March, and he declared that armed groups in almost a dozen countries had responded positively by early in April. Yet rather than seizing the moment to back the initiative, the Council stumbled into three months of fighting about it, while many of the armed groups that welcomed the UN appeal resumed hostilities.

With Council members looking forward to an August lull in business especially after the tedium of months of online meetings it is time for them to take stock of what the Councils halting reaction to the pandemic reveals about the body, and to consider how the Secretary-General and Council members might still salvage something useful from Resolution 2532.

A Trivial Process

The Councils disarray over the novel coronavirus has certainly been a setback for its aspirations to address non-traditional security threats, as UN officials term a grab bag of challenges including pandemics, climate change and organised crime.

The Council has engaged to some degree with these challenges in the post-Cold War era, first taking up health in the context of HIV/AIDS in 2000 and then climate change starting in 2007. With a handful of exceptions, its work in these areas has been fairly tentative, and some current members of the body would like to see it take a more active role. Belgium and Germany have, for example, prioritised climate change, while Estonia has made cybersecurity its flagship issue. But these members face considerable pushback from China and Russia, which insist that the Council should concentrate on more traditional peace and security issues, and the present U.S. administration, which has a particular dislike for talk of climate change. In July, Germany decided to drop proposals for a resolution focusing on climate security authorising a UN envoy to tackle the subject after the U.S. promised to veto it.

Of these non-traditional threats, pandemic response has often seemed to be the most promising area, aside from organised crime, for Security Council action. In 2014, otherwise a difficult year of UN diplomacy over Syria and Ukraine, the Council united around a resolution endorsing international efforts to stamp out Ebola in West Africa. Through 2019 and 2020, the Council monitored a further Ebola outbreak in the Democratic Republic of Congo where UN peacekeepers worked with health experts to get aid into volatile regions. Prior to COVID-19, Germany clairvoyantly signalled that it wanted to use its Council term to spur discussion of pandemics, a personal priority for Chancellor Angela Merkel, as well as climate change.

Yet COVID-19 demonstrated at least two significant weaknesses concerning its policy tools and major power politics in the Councils capacity to deal with global health crises.

First, as a practical matter, the Councils toolkit is still limited. As the pandemic spread, it was not entirely evident what the Security Council could concretely do about it, beyond expressing concern. In 2014, the Councils tools for dealing with Ebola in West Africa were pretty clear. The UN had peacekeepers in Liberia who could assist with logistics and other aspects of the medical response, as well as a significant humanitarian and development presence in the other two countries affected by the disease, Guinea and Sierra Leone. By throwing its weight behind use of these UN assets to counter the disease, and encouraging member states to pledge additional resources to the effort, the Council added urgency to the global response to Ebola, while the U.S. largely coordinated the successful effort to contain the outbreak. (It helped that the U.S. and China worked collaboratively to fight the disease, rather than lobbing political grenades at each other as they have in the COVID-19 era.)

By contrast, COVID-19 presents a threat of a different scale and nature. As of March, there were reported cases on every inhabited continent. In most places where it struck early, like Iran and Italy, there was little if any UN humanitarian or security presence, reducing the Security Councils ability to forge a response. Had a major power launched a global effort to marshal resources to meet the crisis, as the U.S. did with Ebola in 2014, the Council might have lent its political heft to supporting that. But that did not happen: Washington sat on the sidelines and its biggest competitor, Beijing, did not step into its shoes.

Lacking many of the options that had been available to the UN in the Ebola crisis, the Council members spent early April tussling over the scope of any potential resolution. All agreed that the Council should endorse efforts by UN peace operations to help tackle the disease in their areas of deployment a task that the blue helmets undertook even without Council urging, while trying to avoid spreading the disease themselves. But while Tunisia, which led discussions among the ten elected Council (E10) members, initially envisaged a broad resolution with passages calling for international cooperation on public health issues, including training medics and developing a COVID-19 vaccine, the majority of diplomats felt that the Council should not (in the words of one European official) bite off more than it can chew by commenting on non-security-related matters.

It was against this backdrop that both the E10 and the five permanent (P5) Council members, led by France, began to focus on Guterres call for a global ceasefire as a well-defined flagship topic that both served the purposes of pandemic response and clearly fell within the bodys remit of preserving international peace and security. Although some of the P5, including Russia, the UK and the U.S., made it clear that they would not sign onto any text curtailing their conduct of counter-terrorism operations (and indeed Resolution 2532 contains caveats allowing them to fight on), nobody was fundamentally opposed to the ceasefire idea.

The second Council weakness that the episode highlighted is that, even when confronting a true global threat like the virus, policy is often beholden to politics. While everyone could get behind a global ceasefire in theory, it was not anyone's overwhelming priority, and China and the U.S. in particular had bigger point-scoring goals to pursue. The U.S. saw the resolution as a chance to try to assign China responsibility for the disease (at first demanding that any Security Council text refer to Wuhan virus) while refusing to accept even a passing reference to the World Health Organization (WHO) after President Donald Trump suspended funding to that body in April. Chinas immediate priority was to block any implicit or explicit criticism of its handling of the disease, but it also saw an opportunity to embarrass the U.S. for abandoning the WHO and cast Washington as a spoiler on the Council. While Chinese and U.S. officials in New York were ready to compromise on an indirect reference to the WHO in May, Washington nixed this deal, killing off further Council discussions of COVID-19 until late June.

The basic reason that the Security Council underperformed in the face of COVID-19 was, therefore, exactly the reason the Council underperforms on many issues: big power tensions. This fact hardly went unnoticed in New York. Some Council members favoured calling a vote on the COVID-19 resolution in early May, to see if either Beijing or Washington would really veto it. France, which had led P5 discussions of the process, demurred, along with Tunisia. One diplomat observed that the whole process was trivial, as both China and the U.S. placed throwing political punches above securing a resolution, while other Council members did not feel strongly enough about the idea to challenge them.

While France and Tunisia eventually found a formula for referring to the WHO that everyone could accept, the whole episode was discouraging for those who would like to see the Council do more to address non-traditional threats. It left the sense that the Council presently has neither a solid policy framework for dealing with pandemics on the scale of COVID-19 or their security implications nor the collective political will necessary to tackle such challenges.

What Now?

With Resolution 2532 wrapped up, the Council has turned to other matters, although none is a cause for celebration. July saw Russia succeed in pressing to reduce the number of crossing points for humanitarian assistance into rebel-held areas of Syria to just one; by 2021, the number is likely to be zero. The main topic of conversation around the Council these days is the possibility that the U.S. will force a major crisis among the P5 in the coming months by demanding the renewal of sanctions on Iran. New York-based diplomats are aware of the pandemics ongoing challenges, of course. They have heard sobering reports from UN officials on the diseases potential to spark food crises, which could in turn lead to violence. But there is little sign that Council members will use Resolution 2532 as a starting point for initiatives to address particular conflicts or even engage the UN Secretariat on how to follow up.

Can any good still come out of the Secretary-Generals call or out of Resolution 2532? Back in April, when it still seemed possible that the Council could move quickly to a resolution, Crisis Group argued that it could have two main benefits. The first, as noted above, was simply to send a positive political signal about the main UN powers unity in the face of the pandemic. This nod, we argued, might also encourage those conflict parties that signed onto the Secretary-Generals ceasefire idea early to maintain their cessations of hostilities. Whether or not the gambit would have worked and there are, of course, strong reasons to doubt that it would have the Council missed that chance.

But we also suggested in April that a Council resolution could have a second, more procedural, benefit, noting that it could create a formal framework for Guterres to monitor and update the Council on ceasefire implementation. The idea was not so much that the Council would use its enforcement powers such as sanctions to compel states or guerrillas to honour COVID-19 ceasefires. It could, however, offer the Secretary-General a platform to report on where conflict parties were taking real steps to contain the virus and where others were failing to do so.

This idea may still be salvageable: Resolution 2532 does offer Guterres a platform, requesting that he provide updates to the Security Council on the UN efforts to address the COVID-19 pandemic in countries in situations of armed conflict or affected by humanitarian crises. This matter is partly technical: the Secretary-General will need to keep the Council up to date on how peacekeeping operations, political missions and other actors are adapting to the virus. But with a bit of creativity, he can also interpret this mandate as permitting him to talk far more generally with Council members about how the pandemic is affecting the international security landscape. After all, it is clear that the coronavirus is not merely a pathogen causing a health crisis but also is a catalyst for economic shocks that can (as we have already seen in Lebanon) lead to political crises and disorder. It is not clear how the disease will play out region by region and so far it has not been quite as destructive in some weak countries as seemed likely in March but it would be a brave ambassador at the UN who would bet that the health, economic and social fallout from COVID-19 will not lead to more political instability.

Secretary-General Guterres should take an expansive view of his mandate to report on COVID-19 to the Council offering Council members early warnings of potential virus-related crises and conflicts based on UN economic and humanitarian analysis as well political reporting. If the Secretary-General feels uncomfortable about calling out specific states in writing, he can also offer these warnings orally in closed meetings.

To date, the Council has proved ill prepared to respond to a global challenge on the scale of COVID-19. Secretary-General Guterres cannot resolve the rifts among the P5 that severely hamper the Council. But he can at least use Resolution 2532 as the basis to warn Council members of the pandemics evolving security implications, in the hope that they will respond a little better to the risks it creates than they have so far.

Contributors

Richard GowanUN Director

Ashish PradhanSenior Analyst, UN Advocacy and Research

Read the original post:

Salvaging the Security Council's coronavirus response - World - ReliefWeb

Stocks in the news: YES Bank, DMart, Infosys, BHEL, Tata Motors and Apollo Hospitals – Economic Times

Nifty futures on the Singapore Exchange traded 42points, or 0.38 per cent higher at 10,953.50, in signs that Dalal Street was headed for a positive start on Tuesday. Here are a few stocks which may buzz the most in today's trade:

YES Bank: Moody's Investors Service has upgraded YES Bank's long-term foreign-currency issuer rating to B3 from Caa1 after the banks equity capital raise of Rs 15,000 crore. The outlook on the private lenders ratings has been changed to stable from positive.

Avenue Supermarts: The company, which runs the DMart retail chain, saw its online sales more than double during FY20 to Rs 354 crore despite operating only in Mumbai. The country's most valuable retailer by market capitalisation, however, widened its net loss by 36 per cent to Rs80 crore in the four-year old e-commerce subsidiary - Avenue E-Commerce.

Infosys: The National Bank of Bahrain (NBB) has chosen Infosys Finacle to digitally transform its transaction banking business, the IT company said on Monday.

Tata Motors: Tata Motors Chairman N Chandrasekaran said to the company's shareholders that the automaker was charting out a disciplined growth path by focussing on generating positive cashflows, reducing inefficiencies and investing in future product development.

BHEL: State-run engineering major BHEL said it is still grappling with uncertainties with regard to resumption of normal business operations as rising COVID-19 infection cases have led to labour shortage and supply chain disruptions.

Apollo Hospitals: Munchener Ruckversicherungs-Gesellschaft Aktiengesellschaft In Munchen sold its entire 1.72 per cent stake or 2,397,380 shares in Apollo Hospitals at Rs 1,600.43 per share.

Gujarat Gas, PI Industries: Dixon Technologies, Godrej Consumer Products, Gujarat Gas, Marksans Pharma, Hikal, Neuland Laboratories, Tata Consumer Products, PI Industries: These companies are scheduled to announce their June quarter earnings on Tuesday.

JSW Energy: Sajjan Jindal led-JSW Energy, one of the only private power utilities in India which was looking to expand its thermal power capacity through acquisitions has pulled the plug on the plan and aims to focus on renewable energy only, after calling off the deal to buy an asset from GMR.

Bank of India: State-owned Bank of India is planning to raise Rs 7000-8000 crore in combination of equity and bonds to boost capital even as it steps up recovery to improve earnings.

Kirloskar Electric: Kirloskar Electric Company on Monday said uncertainty in its operations on account of COVID-19 pandemic continues due to lockdown in various places.

GMR Infrastructure: The infra firm is working on disinvestment of non-core assets including land and hopes to yield "significant value" even from 50 per cent of land monetization, PTI reported.

Century Plyboards: The company announced the use of nano technology in manufacturing of its plywood and laminate products. The highly activated and energized nanoparticles physically rupture and kill viruses coming in contact with it.

Read more:

Stocks in the news: YES Bank, DMart, Infosys, BHEL, Tata Motors and Apollo Hospitals - Economic Times

Stoke Therapeutics to Present at Upcoming Investor Conferences in August – Business Wire

BEDFORD, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc., (Nasdaq: STOK), a biotechnology company pioneering a new way to treat the underlying cause of genetic diseases by precisely upregulating protein expression, today announced that members of management will present at three upcoming investor conferences in August:

2020 Wedbush PacGrow Healthcare Virtual ConferenceDate: Tuesday, August 11, 2020Time: 11:30 a.m. ET

BTIG Virtual Biotechnology ConferenceDate: Tuesday, August 11, 2020Time: 2:00 p.m. ET

Canaccord Genuity 40th Annual Growth ConferenceDate: Wednesday, August 12, 2020Time: 2:30 p.m. ET

A live audio webcast of each presentation will be available on the Investors & Media section of Stokes website at https://investor.stoketherapeutics.com/. A replay of the webcasts will be available for 30 days following the presentations.

About Stoke Therapeutics

Stoke Therapeutics, Inc. (Nasdaq: STOK), is a biotechnology company pioneering a new way to treat the underlying causes of severe genetic diseases by precisely upregulating protein expression to restore target proteins to near normal levels. Stoke aims to develop the first precision medicine platform to target the underlying cause of a broad spectrum of genetic diseases in which the patient has one healthy copy of a gene and one mutated copy that fails to produce a protein essential to health. These diseases, in which loss of approximately 50% of normal protein expression causes disease, are called autosomal dominant haploinsufficiencies. The companys lead investigational new medicine is STK-001, a proprietary antisense oligonucleotide (ASO) that has the potential to be the first disease-modifying therapy to address the genetic cause of Dravet syndrome, a severe and progressive genetic epilepsy. Stoke is headquartered in Bedford, Massachusetts with offices in Cambridge, Massachusetts. For more information, visit https://www.stoketherapeutics.com/ or follow the company on Twitter at @StokeTx.

Read this article:

Stoke Therapeutics to Present at Upcoming Investor Conferences in August - Business Wire

The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 20192025 – GlobeNewswire

New York, Aug. 04, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Cell & Gene Therapy Market - Global Outlook and Forecast 2020-2025" - https://www.reportlinker.com/p05827567/?utm_source=GNW 90% during the period 20192025.

The global cell and gene therapy market is one of the fastest-growing segments in the regenerative medicine market. The market is expected to grow at a faster pace during the forecast period. The demand can be attributed to the growing prevalence of several chronic diseases such as cancer, cartilage related problems, wounds, diabetic foot ulcer, genetic disorders, and other rare diseases across the globe. The prevalence of cancer and diabetes is increasing in the global population, which is influencing the growth of the market. There is a large unmet need in the treatment available, which is filled by cell and gene therapies. The market is growing due to the increased availability of funding from various public and private institutions. Besides, there is increased support from regulatory bodies for product approval. Several governments are creating awareness of cell and gene therapies in the population.

The following factors are likely to contribute to the growth of the cell and gene therapy market during the forecast period: Increase in Strategic Acquisition Activities Increased Funding for Cell & Gene Therapy Products Expanding Applications of Cell and Gene Therapies Increased in the Patient Pool

The study considers the present scenario of the cell and gene therapy market and its market dynamics for the period 2019?2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The report offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent ones operating in the market. Cell And Gene Therapy Market Segmentation The global cell and gene therapy market research report includes a detailed segmentation by product, disease, end-user, and geography. In 2019, the cell therapy segment accounted for a market share of over 53% in the global cell and gene therapy market. The segment is expected to grow at a steady rate during the forecast period due to the increase in the target population and the rise in the number of countries preferring cell therapies in their patients. Increased therapeutic benefits are attracting several countries to invest in this technology and conduct a high number of clinical trials. However, the lack of advanced infrastructure in developing countries is hindering the growth of the segment.

In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.

The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.

In 2019, the oncology segment accounted for a share of over 40% in the global cell and gene therapy market. Oncology has been one of the targets of intense research for the gene therapy procedures & approach. More than 60% of on-going gene therapy clinical trials are targeting cancer. The segment is expected to grow at a promising rate on account of the high prevalence of cancer diseases, especially in low and middle-come countries. The market is growing at a double-digit CAGR, which is expected to help the segment as many cell and gene therapy for cancer are commercially available.

The dermatology application segment in the cell and gene therapy includes wound care management among patients. Vendors are focusing on the development and commercialization of advanced wound care products for the treatment of chronic and acute wounds, thereby increasing the growth of the wound care market. The increased pervasiveness of diabetics is increasing acute and chronic wounds, including surgical wounds, pressure ulcers, diabetic foot ulcers, and other wounds.

Segmentation by Product Cell Therapy Gene Therapy Segmentation by Disease Dermatology Musculoskeletal Oncology Genetic Disorders Others Segmentation by End-user Hospitality Cancer Care Centers Wound Care Centers Ambulatory Surgical Centers Others

INSIGHTS BY GEOGRAPHY In 2019, North America accounted for a share of over 60% of the global cell and gene therapy market. There are more than 530 regenerative medicine companies, including cell and gene therapy manufacturing developers. The number of products approved in North America grew significantly in 2019, with developers filed for marketing authorization for 10+ regenerative medicines, many of which we expect to be approved in 2020. Within the next 12 years, the number of approved gene therapies is expected to double. The US and Canada are the major contributors to the cell and gene therapy market in North America. Regulatory bodies are supporting several investigational products, fast track approvals, RMAT designation for the faster approval of the product into the market. The alliance for regenerative medicine and Medicare and Medicaid is working together to bring the structured reimbursement channels for cell and gene therapies.

Segmentation by Geography North America o US o Canada Europe o UK o Germany o France o Spain o Italy APAC o China o Japan o South Korea o Australia o India Latin America o Brazil o Mexico Middle East & Africa o Saudi Arabia o Turkey o South Africa o UAE

INSIGHTS BY VENDORS The global cell and gene therapy market is highly dynamic and characterized by the presence of several global, regional, and local vendors offering a wide range of therapies. Dendreon, Gilead Sciences, Novartis, Organogenesis, Osiris Therapeutics, Vericel, Amgen, and Spark Therapeutics are the leading players in the market with significant shares. Vendors such as NuVasive, APAC Biotech, Nipro, Orthocell, bluebird bio, J-TEC, and Terumo are the other prominent players in the market with a presence, especially in the cell therapy market. Most leading players are focusing on implementing strategies such as product launches and approvals, marketing and promotional activities, acquisitions, increased R&D investments, and strengthening their distribution networks to enhance their share and presence in the market.

Prominent Vendors Gilead Sciences Spark Therapeutics Novartis Organogenesis Amgen Osiris Therapeutics Dendreon Vericel

Other Prominent Vendors Anterogen Tego Sciences Japan Tissue Engineering JCR Pharmaceuticals Medipost MolMed AVITA Medical CollPlant Biosolution Stempeutics Research Kolon Tissue Gene Orchard Therapeutics Sibiono GeneTech NuVasive Corestem Pharmicell Shanghai Sunway Biotech RMS Regenerative Medical System Takeda Pharmaceutical Company CHIESI Farmaceutici CO.DON AnGes GC Pharma Human Stem Cells Institute JW CreaGene APAC Biotech Nipro Terumo Orthocell bluebird bio

Key Questions Answered 1. What is the cell and gene therapy market size and growth rate during the forecast period? 2. What are the factors impacting the growth of the cell and gene therapy market share? 3. How is the growth of the healthcare segment affecting the growth of the cell and gene therapy market? 4. Who are the leading vendors in the cell and gene therapy market, and what are their market shares? 5. Which product type/ end-user type/region is generating the largest revenue in the Asia Pacific region?Read the full report: https://www.reportlinker.com/p05827567/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

Link:

The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 20192025 - GlobeNewswire

Cochlear implant uses LEDs to tackle hearing loss – Optics.org

04Aug2020

University of Gttingen device points towards more efficient treatments.

Cochlear implants are an established treatment, using a microphone to detect sound and converting that sound into electrical impulses, split into several channels for different frequency ranges. Electrode contacts, typically 12 to 24 in number, then deliver the electrical impulses to the ganglion neurons of the cochlea.

But these devices can offer poor quality sound encoding, partly due to the large lateral spread of electrical current from each electrode, stimulating too many auditory neurons at the same time. A project at the University of Gttingen has now developed a light-based alternative device, reported in Science Translational Medicine.

"The lateral spread is considered the major bottleneck of electrical implants," said Tobias Moser of the University of Gttingnen. "Despite efforts such as multipolar stimulation and current steering, it seems hard or even impossible to overcome."

Neurons are not typically light sensitive, although the growing field of optogenetics has found elegant ways to induce neurons into expressing light-sensitive proteins through genetic modifications in so-called transgenic animals, and making the neurons react to illumination by laser pulse.

Since light can be better confined in space than electric current, optogenetic techniques could allow cochlea stimulation to be made more efficient. However, light sources for optogenetics have usually been individual GaN-based LEDs and optical fibers coupled to external lasers.

In designing an optical cochlear implant (oCI) for auditory treatment and future clinical translation, the Gttingen project had to develop multichannel devices suitable for this very specific purpose.

The eventual design featured a linear array of 10 LED chips, each 270 by 220 microns and emitting at 457 nanometers, integrated onto microfabricated 15-micron-thick polyimide-based carriers with interconnecting lines to address individual LEDs.

Hearing restored

"The linear array of 10 LEDs at the oCI tip was designed with a pitch of 500 or 350 microns," noted the project in its published paper. "In addition, an array with four LEDs containing a temperature sensor integrated beneath the first LED chip enables a precise resistance measurement, and thus allows monitoring of potential temperature increase inside the implant."

Having optimized the design for rodent ears, the project inserted the device into transgenic rats and characterized the oCI's stimulation of the animals' auditory nerves. Comparing the spatial spread of excitation from the LEDs of the oCI to that from electrodes of a conventional electrical implant by monitoring the animal's midbrain allowed the frequency selectivity of the oCI device to be characterized.

In behavioral experiments, the team began with rats with normal hearing and trained them to perform a behavior driven by sound. After deafening the rats, the team implanted the oCI device and found that the animals could still perform the acoustically trained behavior with the aid of the multichannel implant.

According to the project, results showed that use of gene therapy and the optical implant in conjunction led to an improved frequency selectivity compared with the electrical alternative, and future enhancements to both the size of LEDs and the spread of light from each emitter could enhance this parameter further.

Although further work will be needed before clinical trails using the device can start, including more detailed studies of behavioral analysis connected with the technique, the team has founded a spin-out company, OptoGenTech, to potentially assist translation of the gene therapy and oCI combination into a human clinical trial and, eventually, bring it to market.

"This is the first demonstration and characterization of preclinical hearing restoration by a complete multichannel oCI system based on LEDs," commented Moser.

View post:

Cochlear implant uses LEDs to tackle hearing loss - Optics.org

Mesothelioma Compensation Center Urges the Family of a Power Plant Worker with Recently Diagnosed Mesothelioma to Call Attorney Erik Karst of Karst…

HOUSTON, July 29, 2020 /PRNewswire/ -- The Mesothelioma Compensation Center says, "We are appealing to the family of a power plant worker nationwide who has just been diagnosed with mesothelioma to please call 800-714-0303 for direct access to attorney Erik Karst of the law firm of Karst von Oiste. Erik Karst and his colleagues at Karst von Oiste have been assisting power plant workers for decades and they are responsible for over a billion dollars in financial compensation results for people like this.

"Financial compensation for a power plant worker with this rare cancer caused by asbestos exposure might exceed a million dollars-if the person or family hires an experienced mesothelioma lawyer. Erik Karst is one of the nation's leading mesothelioma attorneys-and he will know how to help you or your loved one."www.karstvonoiste.com

The Mesothelioma Compensation Center is also urging the wife or adult son-daughter of a former power plant worker who had heavy to extreme exposure to asbestos at work to please tell their doctors about his work place exposure to asbestos if he has been hospitalized with pneumonia. Mesothelioma and the Coronavirus have similar symptoms such as pneumonia, high fever, and shortness of breath.

They say, "The average age for a person with mesothelioma in the United States is 72 years old. Mesothelioma could easily be misdiagnosed as the Coronavirus. We do not want a person with mesothelioma to not get compensated in 2020 because they were misdiagnosed with the Coronavirus. If your husband or dad is in the hospital right now with pneumonia and you know for a fact he had significant exposure to asbestos at work-before 1982 please call us at 800-714-0303 so we might try to assist in ensuring a proper diagnosis-if possible."https://MesotheliomaCompensationCenter.Com

The Mesothelioma Compensation Center is Extremely Focused on Helping the Following Types of People with Mesothelioma:

For more information about power plants inthe United Statesplease refer to the US Energy Information Agency's website: https://www.eia.gov/ state/maps.php.

The Mesothelioma Compensation Center specializes in assisting specific types of people who have been diagnosed with mesothelioma. The Center's top priority is assisting US Navy Veterans, shipyard workers, oil refinery workers, public-utility workers, chemical plant workers, manufacturing workers, power plant workers, plumbers, welders, electricians, millwrights, pipefitters, boiler technicians, machinists, nuclear power plant workers, hydro-electric workers or oil and gas field production workers who have been diagnosed with this rare cancer caused by asbestos exposure. In most instances a diagnosed person with mesothelioma was exposed to asbestos in the 1950's, 1960's, 1970's, or 1980's.https://MesotheliomaCompensationCenter.Com

According to the CDC the states indicated with the highest incidence of mesothelioma include Maine, Massachusetts, Connecticut, Maryland, New Jersey, Pennsylvania, Ohio, West Virginia, Virginia, Michigan, Illinois, Minnesota, Louisiana, Washington, and Oregon.

However, a power plant or public utility worker with mesothelioma could live in any state including California, New York, Florida, Texas, Illinois, Kentucky, Tennessee, Mississippi, Georgia, Alabama, Wyoming, Colorado, New Mexico, Nevada, Utah, Arizona, Idaho, or Alaska.www.karstvonoiste.com/

For more information about mesothelioma please refer to the National Institutes of Health's web site related to this rare form of cancer:https://www.cancer.gov/types/mesothelioma.

Media Contact:Michael Thomas800-714-0303241211@email4pr.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/mesothelioma-compensation-center-urges-the-family-of-a-power-plant-worker-with-recently-diagnosed-mesothelioma-to-call-attorney-erik-karst-of-karst-von-oiste-for-his-passion-the-best-client-compensation-results-301101967.html

SOURCE Mesothelioma Compensation Center

Read the original:

Mesothelioma Compensation Center Urges the Family of a Power Plant Worker with Recently Diagnosed Mesothelioma to Call Attorney Erik Karst of Karst...